| P50 | author | Peter Proksch | Q89300559 |
| P2093 | author name string | Matthias U Kassack | |
| | Alexandra Hamacher | |
| | Laura H Engelke | |
| P2860 | cites work | Cancer statistics, 2014 | Q27861018 |
| | New perspectives on targeted therapy in ovarian cancer | Q28082524 |
| | p53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells | Q28198105 |
| | Influence of berry polyphenols on receptor signaling and cell-death pathways: implications for breast cancer prevention | Q28258801 |
| | In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro | Q29617927 |
| | Downregulation of Epidermal Growth Factor Receptor Expression Contributes to alpha-TEA's Proapoptotic Effects in Human Ovarian Cancer Cell Lines | Q33708364 |
| | Estrogen biosynthesis and action in ovarian cancer | Q34496401 |
| | Molecular targets of dietary agents for prevention and therapy of cancer | Q34505253 |
| | Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials | Q34795525 |
| | Subchronic oral toxicity and cardiovascular safety pharmacology studies of resveratrol, a naturally occurring polyphenol with cancer preventive activity | Q35570811 |
| | Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer | Q36678093 |
| | The inhibitory effect of ellagic Acid on cell growth of ovarian carcinoma cells | Q36969635 |
| | Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives | Q37190153 |
| | Therapeutic applications of pomegranate (Punica granatum L.): a review. | Q37203267 |
| | Effects of phytochemicals on ionization radiation-mediated carcinogenesis and cancer therapy | Q37949746 |
| | Resveratrol-based combinatorial strategies for cancer management | Q38121604 |
| | Dietary phenolics against colorectal cancer--From promising preclinical results to poor translation into clinical trials: Pitfalls and future needs | Q38360706 |
| | EGFR mediates LPA-induced proteolytic enzyme expression and ovarian cancer invasion: inhibition by resveratrol | Q39249383 |
| | Resveratrol exerts differential effects in vitro and in vivo against ovarian cancer cells. | Q39313933 |
| | Resveratrol downregulates Akt/GSK and ERK signalling pathways in OVCAR-3 ovarian cancer cells | Q39414212 |
| | Combinations of resveratrol, cisplatin and oxaliplatin applied to human ovarian cancer cells. | Q39418533 |
| | Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells | Q39868633 |
| | Acquired cisplatin resistance in the head-neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1. | Q39952644 |
| | Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549. | Q40462593 |
| | Ellagic acid and quercetin interact synergistically with resveratrol in the induction of apoptosis and cause transient cell cycle arrest in human leukemia cells. | Q40465810 |
| | Comparison of the usefulness of the MTT, ATP, and calcein assays to predict the potency of cytotoxic agents in various human cancer cell lines. | Q40479447 |
| | Antitumor-promoting activities of tannic acid, ellagic acid, and several gallic acid derivatives in mouse skin | Q43566563 |
| | IGF-II down regulation associated cell cycle arrest in colon cancer cells exposed to phenolic antioxidant ellagic acid | Q43573071 |
| | Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cells. | Q44084996 |
| | Resveratrol increases serine15-phosphorylated but transcriptionally impaired p53 and induces a reversible DNA replication block in serum-activated vascular smooth muscle cells | Q44367245 |
| | Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells | Q44380816 |
| | In vitro anti-proliferative activities of ellagic acid | Q45181981 |
| | Safety assessment of ellagic acid, a food additive, in a subchronic toxicity study using F344 rats | Q46836090 |
| | Structure-function relationships of the dietary anticarcinogen ellagic acid | Q71067935 |
| | Identification of tricyclic analogs related to ellagic acid as potent/selective tyrosine protein kinase inhibitors | Q71634586 |
| | Isothiocyanates and plant polyphenols as inhibitors of lung and esophageal cancer | Q73224285 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cisplatin | Q412415 |
| | cancer cell line | Q23058136 |
| | ovarian cancer | Q172341 |
| P304 | page(s) | 353-363 | |
| P577 | publication date | 2016-01-10 | |
| P1433 | published in | Journal of Cancer | Q6294901 |
| P1476 | title | Ellagic Acid and Resveratrol Prevent the Development of Cisplatin Resistance in the Epithelial Ovarian Cancer Cell Line A2780. | |
| P478 | volume | 7 | |